On October 26, 2016 GSK reported further sales growth, improved cash flow and sustained pipeline progression in Q3 (Press release, GlaxoSmithKline, OCT 26, 2016, View Source [SID1234516014]). Schedule your 30 min Free 1stOncology Demo! Summary
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For GlaxoSmithKline’s full Q3 results announcement, visit: View Source to view full Q3 results announcement (PDF)
Group sales £7.5 billion, +8% CER, with continued growth across all three businesses
New product sales £1.21 billion +79% (Q1 2016: £821 million; Q2 2016: £1.05 billion) driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro, Incruse, Nucala) and Meningitis vaccines (Bexsero, Menveo)
Improved operating leverage driven by sales growth, delivery of restructuring and integration benefits and continued tight control of costs including targeted reinvestments
Q3 total earnings per share 16.6p, -1% CER, impacted by charges resulting from increases in valuations of Consumer Healthcare and HIV businesses
Q3 core earnings per share 32p, +12% CER
Continue to expect 2016 core EPS percentage growth to be 11-12% CER
Q3 net cash inflow from operations of £1.8 billion (Q3 2015: £0.5 billion)
19p dividend declared for Q3. Continue to expect 80p for FY 2016 and 2017
Sustained delivery in R&D pipeline